1-7 of 7
Monika A. Niewczas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies

Hetal S. Shah, Lorena Ortega Moreno, Mario Luca Morieri, Yaling Tang, Christine Mendonca, Jenny Marie Jobe, Jonathan B. Thacker, Joanna Mitri, Stefano Monti, Monika A. Niewczas, Subramaniam Pennathur, Alessandro Doria
Journal: Diabetes Care
Diabetes Care 2022;45(8):1882–1892
https://doi.org/10.2337/dc21-1789
Published: 26 July 2022
View articletitled, Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies
Open the PDF for Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies in another window
Journal Articles

Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy

Daniel Gordin, Hetal Shah, Takanori Shinjo, Ronald St-Louis, Weier Qi, Kyoungmin Park, Samantha M. Paniagua, David M. Pober, I-Hsien Wu, Vanessa Bahnam, Megan J. Brissett, Liane J. Tinsley, Jonathan M. Dreyfuss, Hui Pan, Yutong Dong, Monika A. Niewczas, Peter Amenta, Thorsten Sadowski, Aimo Kannt, Hillary A. Keenan, George L. King
Journal: Diabetes Care
Diabetes Care 2019;42(7):1263–1273
https://doi.org/10.2337/dc18-2585
Published: 10 May 2019
View articletitled, Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy
Open the PDF for Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy in another window
Includes: Supplementary data
Journal Articles

Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390

Monika A. Niewczas, Andrzej S. Krolewski
Journal: Diabetes Care
Diabetes Care 2017;40(8):e109–e110
https://doi.org/10.2337/dci17-0009
Published: 11 July 2017
View articletitled, Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390
Open the PDF for Response to Comment on Niewczas et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383–390 in another window
Journal Articles

Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease

Monika A. Niewczas, Anna V. Mathew, Stephanie Croall, Jaeman Byun, Melissa Major, Venkatta S. Sabisetti, Adam Smiles, Joseph V. Bonventre, Subramaniam Pennathur, Andrzej S. Krolewski
Journal: Diabetes Care
Diabetes Care 2017;40(3):383–390
https://doi.org/10.2337/dc16-0173
Published: 13 January 2017
View articletitled, Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease
Open the PDF for Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease in another window
Includes: Supplementary data
Journal Articles

Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria

Jan Skupien, James H. Warram, Monika A. Niewczas, Tomohito Gohda, Maciej Malecki, Josyf C. Mychaleckyj, Andrzej T. Galecki, Andrzej S. Krolewski
Journal: Diabetes Care
Diabetes Care 2014;37(9):2601–2608
https://doi.org/10.2337/dc13-1983
Published: 07 August 2014
View articletitled, Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria
Open the PDF for Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5–18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria in another window
Includes: Supplementary data
Journal Articles

Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria

Andrzej S. Krolewski, Monika A. Niewczas, Jan Skupien, Tomhito Gohda, Adam Smiles, Jon H. Eckfeldt, Alessandro Doria, James H. Warram
Journal: Diabetes Care
Diabetes Care 2014;37(1):226–234
https://doi.org/10.2337/dc13-0985
Published: 11 December 2013
View articletitled, Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria
Open the PDF for Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria in another window
Journal Articles

High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes: Results of a 6-year follow-up

Linda H. Ficociello, DSC, Elizabeth T. Rosolowsky, MD, MPH, Monika A. Niewczas, MD, PHD, Nicholas J. Maselli, BA, Janice M. Weinberg, SCD, Ann Aschengrau, SCD, John H. Eckfeldt, MD, PHD, Robert C. Stanton, MD, Andrzej T. Galecki, MD, PHD, Alessandro Doria, MD, PHD, MPH, James H. Warram, MD, SCD, Andrzej S. Krolewski, MD, PHD
Journal: Diabetes Care
Diabetes Care 2010;33(6):1337–1343
https://doi.org/10.2337/dc10-0227
Published: 23 March 2010
View articletitled, High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes: Results of a 6-year follow-up
Open the PDF for High-Normal Serum Uric Acid Increases Risk of Early Progressive Renal Function Loss in Type 1 Diabetes: Results of a 6-year follow-up in another window